Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Myotonic Dystrophy Treatment Market Snapshot (2023 to 2033)

The global Myotonic Dystrophy Treatment Market size is expected to be valued at US$ 874.39 Million in 2023. With the strategic initiative adopted by market players and strict regulatory framework, the overall demand for Myotonic Dystrophy Treatment is projected to grow at a CAGR of 12.3% between 2023 and 2033, totaling around US$ 2,789.35 Million by 2033.

Data Points Key Statistics
Myotonic Dystrophy Treatment Market Value 2023 US$ 874.39 Million
Myotonic Dystrophy Treatment Market Projected Value (2033) US$ 2,789.35 Million
Myotonic Dystrophy Treatment Market CAGR (2023 to 2033) 12.3%

As per the World Health Organization, cardiovascular diseases accounted for 17.7 million deaths in 2015, representing 31% of global deaths. Factors such as an increase in research and development, introduction of novel disease therapies, rise in demand for effective therapies among patients, as well as an upsurge in the prevalence of the disease are expected to propel the growth of the myotonic dystrophy market in the near future.

According to the Centers for Disease Control and Prevention, in 2016, the prevalence of myotonic muscular dystrophy was 1 in every 8000 people. The rise in the prevalence of chronic diseases such as cardiovascular, neurovascular, and arthritis and the increase in health care insurance coverage are the other factors anticipated to augment the market growth in the forthcoming years.

Furthermore, increasing demand for effective treatment methods is another major factor fueling the demand for myotonic dystrophy treatment during the forecast period. Also, wider coverage in healthcare insurance as well as incidences of chronic illnesses like arthritis, neurovascular, and cardiovascular conditions are further expected to augur well for the global myotonic dystrophy therapeutics market in the near future.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Myotonic Dystrophy Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for Myotonic Dystrophy Treatment is projected to increase at a CAGR of 12.3% during the forecast period between 2023 and 2033, reaching a total of US$ 2,789.35 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.6%.

According to Future Market Insights, a market research and competitive intelligence provider, the Myotonic Dystrophy Treatment Market was valued at US$ 778.62 Million in 2022.

Compared to several other products of myotonic dystrophy, corticosteroids are possibly to emerge as the top-selling products during the analysis period. By 2029 end, corticosteroids are expected to exceed US$ 9,000 million in revenue. Numerous scientific research has found that compared to numerous products to treat myotonic dystrophy, corticosteroids help to improve muscle strength for up to two to five years, however, the long-term benefit of corticosteroids is yet a vague concept.

Additionally, nowadays, more clinical trials are being conducted to assess potential treatments for myotonic dystrophy. The only approved pharmacological therapy for the management of myotonic dystrophy is an anti-inflammatory regimen based on corticosteroids. In recent times, there has been a huge increase in the discovery and development of pharmaceutical drugs. Approximately all major companies are now focusing on Research and Development, possibly leaving a significant impact on the market in the upcoming years.

Which Drivers underpin Myotonic Dystrophy Treatment Industry Expansion?

Rising Incidence of Muscular Dystrophies to Accelerate the Market Growth

As per the Karger Journal in 2014, the global prevalence of muscular dystrophies accounted between 19.8 and 25.1 per 100,000 people every year with myotonic dystrophy (0.5-18.1 per 100,000), myotonic dystrophy (1.7-4.2) and facioscapulohumeral muscular dystrophy (3.2-4.6 per 100,000) to be the most common types of disorders.

The initial research phase of the therapies and ongoing clinical trials for the development of innovative products are expected to drive the global muscular dystrophy treatment market. In addition, specific guidance for drug development for muscular dystrophy drugs published by the US FDA in 2015, is expected to accelerate new drug development for the treatment of the disorder.

The emergence of disease-modifying therapies as a replacement for the unmet medical needs of patients, who are not amenable to mutation-specific drugs is expected to accelerate the growth of the myotonic dystrophy treatment market during the analysis period.

Availability of Potential Pipeline Candidates to Fuel the Market Growth

The advent of drugs for the treatment of Myotonic Dystrophy is on the new horizon, which is a major factor that is expected to escalate the market growth over the forecast period. Other factors such as the growing target population, emergence of mutation-specific therapies, and favorable government initiatives are anticipated to boost the revenue share of the myotonic dystrophy market during the analysis period.

Additionally, a surge in the prevalence of myotonic dystrophy is another major factor that is considered to fuel the demand of the market. This, in turn, is propelling the launch of newly formulated pipeline drugs required for the treatment of serious patients. Further, many potential candidates are in their final stages of development and are expected to boost the market growth over the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors are limiting the Growth of Myotonic Dystrophy Treatment Market?

No Cure for the Progressive Disorder to Restrain the Market Growth

One of the major factors that are expected to hamper the growth of the myotonic dystrophy market includes the fact that myotonic dystrophy is a progressive disorder, which means that the severity of the disease increases over time. Thus, early interventions in the myotonic muscular dystrophy market, such as those that are used to treat other forms of muscular dystrophy, are not normally effective in treating myotonic dystrophy patients.

Additionally, since myotonic dystrophy is a genetic condition, there is no known cure and no trustworthy way to slow or stop the progression of the disease. Moreover, the presence of alternative herbal therapies is another factor that is likely to impede market growth during the forecast period.

High Cost Associated with Myotonic Dystrophy Drugs & Lack of Awareness to Limit the Market Growth

Factors such as the huge expenditure associated with myotonic dystrophy agents, as well as the huge drug development and associated processes are anticipated to create hindrances to the growth of the myotonic dystrophy treatment market over the analysis period.

In addition, the lack of awareness about the diseased condition, unavailability of several awareness programs, adverse effects related to the drugs, and strict regulatory frameworks are some other factors that are projected to limit the market growth in the forthcoming years.

Region-wise Insights 

Will North America Continue Dominance in the Global Myotonic Dystrophy Treatment Market?

The surge in Patients Suffering from Myotonic Dystrophy in the Region to Fuel the Market Growth

The Myotonic Dystrophy Treatment Market in North America is expected to accumulate the highest market share of 48% in 2023.

As per the Centers for Disease Control and Prevention estimates in 2007, 349 out of 2.37 million males aged 5 to 24 years were reported to have muscular dystrophy in the US. North America is expected to dominate the global myotonic dystrophy treatment market, attributed to factors including the absence of marketed pharmacological therapies indicated to treat muscular dystrophy, the rising prevalence of the disease, and rising research and development for producing effective drugs.

Additionally, factors such as new product innovations, high healthcare expenditure, and government awareness programs are expected to fuel market growth in the United States. In addition, the regional market is anticipated to expand as more clinical trials are conducted globally, particularly in the United States. The region is expected to hold the highest CAGR of 12.2% during the forecast period.

How Will the Growth of the Myotonic Dystrophy Treatment Market unfold in Asia Pacific?

Increase in Research and development activities in the Region to Fuel the Market Growth

The Myotonic Dystrophy Treatment Market in Asia Pacific is expected to accumulate the highest market share of 47% in 2023.

The Asia Pacific hypophosphatasia market is anticipated to register significant growth during the analysis period, attributed to factors such as an increase in geriatric patients, and high awareness associated with treatment.

In Asia Pacific, Japan is expected to provide the largest market opportunity. In 2017, Japan displayed the drug candidate, DS-5141b, for Duchenne muscular dystrophy on the country’s SAKIGAKE list, a designation that is equal to the US FDA process of accelerated approval. Many initiatives are being taken by market players to boost the regional market.

The rising incidence of myotonic dystrophy, increasing investment in research and development of new treatment options, and a strong pipeline of products under analysis, are the major factors that are anticipated to boost the market growth in Asia Pacific. The region is expected to hold the highest CAGR of 12.1% during the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

By Therapeutics Class, which Myotonic Dystrophy Treatment Category will remain prominent?

Molecular-based Therapies Segment to beat Competition in Untiring Market

On the basis of therapeutics class, the global Myotonic Dystrophy Treatment Market is dominated by the Molecular-based Therapies Segment, which accounts for a share of 44%.

In 2022, the segment generated significant revenue, attributed to the factors such as a strong product pipeline as well as a rise in product launches. In addition, RNA medicine shows promise in DM1 therapeutics by targeting toxic CUG expansions. Moreover, restoring the function of Muscleblind-like proteins is especially important in DM1. In addition, in molecular-based therapies, successful delivery of ASOs is achieved to realize therapeutic effects. The segment is expected to hold a CAGR of 12.2% over the analysis period.

By Distribution Chanel, which Myotonic Dystrophy Treatment Category dominates?

Hospital Pharmacies Segment to Drive the Myotonic Dystrophy Treatment Market

Based on the Distribution Channel, the Hospital Pharmacies segment is expected to witness a significant growth of 43% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 12.1% CAGR over the analysis period.

In the treatment of this mood disorder, a prescription for drugs from a medical professional is needed, this is a crucial reason attributable to the segment's growth. In addition, the expansion of hospital pharmacies owing to increasing investment by the public sector in the healthcare infrastructure in emerging countries is predicted to augment the segmental growth during the forecast period.

The Start-Up Ecosystem: How key Players are opening Frontiers for Future Growth?

Myotonic Dystrophy Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,

  • Founded in 2012, Astellas Gene Therapies has been working as a center of excellence to advance Audentes’ adeno-associated virus (AAV)-based programs for neuromuscular diseases. It is using three gene therapy modalities - specifically, gene replacement, exon skipping, and RNA knockdown.
  • Established in 2018, PepGen is developing a drug that delivers its therapeutic payload not only to skeletal muscle, but also to the diaphragm, cardiac muscle, and the central nervous system. PepGen’s scientists believe this broader delivery capability gives it an edge, and the clinical-stage company has joined the public markets as it sets out to prove its approach.
  • In December 2022, Vertex Pharmaceuticals collaborated with Entrada Therapeutics, to develop intracellular Endosomal Escape Vehicle (EEV) therapeutics. As part of the in-licensing agreement, Entrada will receive an upfront cash payment of $224 million and an equity investment of $26 million.

Who are the Leading Players in the Myotonic Dystrophy Treatment Market?

Prominent players in the Myotonic Dystrophy Treatment Market are Pfizer, Inc., Eli Lilly and Company, Mylan Pharmaceuticals Inc., Wockhardt Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, BioMarin Pharmaceutical, Inc., Asklepios Kliniken GmbH, Hoveround Corporation, and Siemens Healthcare, among others.

Recent Developments:

  • In December 2022, Arthex Biotech S.A. announced that it has met key regulatory milestones in its program to develop ATX-01 in Myotonic Dystrophy Type 1 (DM1), opening a clear path forward to filing an Investigational New Drug (IND) application in the USA and a Clinical Trial Application (CTA) in Europe.
  • In December 2022, AMO Pharma Limited announced the completion of patient enrollment in the company's REACH-CDM study of the investigational therapy AMO-02 in the treatment of congenital myotonic dystrophy. The REACH-CDM pivotal trial is a double-blind, placebo-controlled, randomized study in children and adolescents with congenital-onset myotonic dystrophy intended to support a future submission for marketing authorization in congenital myotonic dystrophy.

Report Scope

Report Attribute Details
Growth Rate CAGR of 12.3% from 2023 to 2033
Market Value in 2023 US$ 874.39 Million
Market Value in 2033 US$ 2,789.35 Million
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Therapeutics Class
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)
Key Countries Profiled
  • The US
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Mylan Pharmaceuticals Inc.
  • Wockhardt Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • BioMarin Pharmaceutical, Inc.
  • Asklepios Kliniken GmbH
  • Hoveround Corporation
  • Siemens Healthcare
  • Lupin
  • ANI Pharmaceuticals
  • Sun Pharma
  • Mallinckrodt
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Isis Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • Valentia Biopharma S.L

Key Segments Covered in the Myotonic Dystrophy Treatment Industry Analysis

Myotonic Dystrophy Treatment Market by Therapeutics Class:

  • Molecular-based Therapies
  • Steroid Therapy

Myotonic Dystrophy Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

Myotonic Dystrophy Treatment Market by Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

What was the market value for Myotonic Dystrophy Treatment in 2022?

As of 2022, the market for Myotonic Dystrophy Treatment was valued at US$ 778.62 Million, as per FMI

At what value did the Myotonic Dystrophy Treatment Market close in 2023?

By 2023-end, sales of Myotonic Dystrophy Treatment closed at a value of US$ 874.39 Million

What was the last 4 years value CAGR for Myotonic Dystrophy Treatment?

From 2018 to 2022, Myotonic Dystrophy Treatment demand expanded at a CAGR of 5.6%

What is the projected forecast CAGR for the Myotonic Dystrophy Treatment Industry from 2023 to 2033?

From 2023 to 2033, Myotonic Dystrophy Treatment sales are expected to flourish at a CAGR of 12.3%

According to FMI, what is the anticipated market value for Myotonic Dystrophy Treatment in 2033?

By 2033, the market value of Myotonic Dystrophy Treatment is expected to reach US$ 2,789.35 Million

By Therapeutics Class, which category ranks first with regard to Myotonic Dystrophy Treatment?

By Therapeutics Class, the Myotonic Molecular-based Therapies segment constitutes the bulk of the market share of 44% in 2022.

By Distribution Channel, which category ranks first with regard to Myotonic Dystrophy Treatment?

By Distribution Channel, the Hospital Pharmacies segment dominates the market with a share of 43% in 2022.

Table of Content

1. Executive Summary | Myotonic Dystrophy Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2018 to 2022

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2018 to 2022

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2018 to 2022

        5.3.1. ISIS-DMPK

        5.3.2. PRO-135

        5.3.3. SRT-152

        5.3.4. VAL-0411

        5.3.5. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2018 to 2022

6. Global Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2018 to 2022

        6.3.1. Hospital

        6.3.2. Clinic

        6.3.3. Home Use

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2018 to 2022

7. Global Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Sales Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Sales Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sales Channel, 2018 to 2022

        7.3.1. Manufacturer/Distributor/Service Provider

        7.3.2. Aftermarket

    7.4. Y-o-Y Growth Trend Analysis By Sales Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Sales Channel, 2018 to 2022

8. Global Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2018 to 2022

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2018 to 2022

        9.2.1. By Country

            9.2.1.1. The US

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Application

        9.2.4. By Sales Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Application

        9.3.4. By Sales Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2018 to 2022

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Application

        10.2.4. By Sales Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Application

        10.3.4. By Sales Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2018 to 2022

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. The UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Application

        11.2.4. By Sales Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Application

        11.3.4. By Sales Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2018 to 2022

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Drug Type

        12.2.3. By Application

        12.2.4. By Sales Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Application

        12.3.4. By Sales Channel

    12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2018 to 2022, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2018 to 2022

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug Type

        13.2.3. By Application

        13.2.4. By Sales Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Application

        13.3.4. By Sales Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. The US

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Type

            14.1.2.2. By Application

            14.1.2.3. By Sales Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Type

            14.2.2.2. By Application

            14.2.2.3. By Sales Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Type

            14.3.2.2. By Application

            14.3.2.3. By Sales Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Type

            14.4.2.2. By Application

            14.4.2.3. By Sales Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Type

            14.5.2.2. By Application

            14.5.2.3. By Sales Channel

    14.6. The UK

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Type

            14.6.2.2. By Application

            14.6.2.3. By Sales Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Type

            14.7.2.2. By Application

            14.7.2.3. By Sales Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Type

            14.8.2.2. By Application

            14.8.2.3. By Sales Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Type

            14.9.2.2. By Application

            14.9.2.3. By Sales Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Type

            14.10.2.2. By Application

            14.10.2.3. By Sales Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Type

            14.11.2.2. By Application

            14.11.2.3. By Sales Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Type

            14.12.2.2. By Application

            14.12.2.3. By Sales Channel

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Type

            14.13.2.2. By Application

            14.13.2.3. By Sales Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Type

            14.14.2.2. By Application

            14.14.2.3. By Sales Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Type

            14.15.2.2. By Application

            14.15.2.3. By Sales Channel

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Drug Type

            14.16.2.2. By Application

            14.16.2.3. By Sales Channel

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Drug Type

            14.17.2.2. By Application

            14.17.2.3. By Sales Channel

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Drug Type

            14.18.2.2. By Application

            14.18.2.3. By Sales Channel

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Drug Type

            14.19.2.2. By Application

            14.19.2.3. By Sales Channel

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Drug Type

            14.20.2.2. By Application

            14.20.2.3. By Sales Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Type

        15.3.3. By Application

        15.3.4. By Sales Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. BioMarin Pharmaceutical Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. F. Hoffmann-La Roche Ltd.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Sanofi

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Ionis Pharmaceuticals, Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Lupin

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Teva

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. ANI Pharmaceuticals

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Viatris

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Novartis

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Sun Pharma

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. Mallinckrodt

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Cataract Surgery Device Market

Published : March 2024

Healthcare

Leukemia Therapeutics Treatment Market

Published : October 2023

Healthcare

Cystic Fibrosis Therapeutics Market

Published : December 2022

Healthcare

PD1 Resistant Head and Neck Cancer Market

Published : December 2022

Explore Healthcare Insights

View Reports

Myotonic Dystrophy Treatment Market